Antimicrobials
Remdesivir (RDV)

Remdesivir (RDV)

Dosing

General Information

See Gilead portal for inclusion/exclusion criteria as these change frequently

Cr, ALT, AST daily

  • Elevated LFTs, hypotension during infusion
  • Contraindicated in pregnancy and breastfeeding

In addition to Gilead Sciences approval for compassionate access, Health Canada Special Access Program (SAP) patient-specific application is also required.

Please note that as of March 22, 2020, Gilead is transitioning from individual compassionate use requests for remdesivir to expanded access programs, details of which are forthcoming. In the interim, remdesivir compassionate use requests have been restricted to pregnant women and children under 18 years with confirmed COVID-19 and severe manifestations of disease

Consult Infectious Diseases in person or by phone for consideration of any directed COVID-19 therapy

Limited efficacy/safety data in Ebola disease; reduces viral load and lung damage in MERS-CoV mice models if given early, superior to lopinavir/ritonavir/IFN; case reports/series on COVID-19, no efficacy data.

Reference: Mulangu S, et al. N Engl J Med. 2019;381(24):2293-2303. Sheahan TP, et al. Nat Commun. 2020;11(1):222. Gilead Sciences. January, 2020 (web link)